We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What to Expect from Keryx (KERX) Stock This Earnings Season?
Read MoreHide Full Article
Keryx Biopharmaceuticals, Inc. is expected to report first-quarter 2017 results on May 4. Last quarter, the company missed expectations by 18.52%. In fact, Keryx’s performance over the last four quarters has been disappointing. The company reported a wider-than-expected loss in three of the trailing four quarters, with an average negative surprise of 35.16%.
Keryx’s share price has increased 0.7% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 4.8%. Let’s see how things are shaping up for the company this quarter.
Factors Influencing This Quarter
Apart from license fees, Keryx’s top line comprises revenues generated by its only marketed product Auryxia (ferric citrate). Auryxia is approved as tablets to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Notably, with Auryxia being the only approved product in Keryx’s portfolio, the company is entirely dependent on it for growth. Launched in the U.S. in late Dec 2014, Auryxia is still in its early stages of commercialization. Insufficient reimbursement and lengthy selling cycles have impacted the ramp up in Auryxia’s sales.
However, Keryx is working on its commercial efforts for Auryxia. In fact, the company is currently working on gaining formulary status for the drug. Additionally, it is operating on contracting the remaining insurance providers to expand patient access to Auryxia. This should enable more contact with the prescribers, both current physicians and those who have not prescribed Auryxia yet. The company expanded its field-based team to 95 sales representatives.
Moreover, Keryx is working on expanding ferric citrate's (the compound name for Auryxia in additional indications) label to include the treatment of iron-deficiency anemia (IDA) in patients with stage III–V non-dialysis dependent chronic kidney disease indication (NDD CKD). In Mar 2017, the FDA accepted the company’s supplemental New Drug Application (sNDA) for Auryxia for review (PDUFA date: Nov 6, 2017). If approved for this indication, Auryxia could be the first FDA-approved oral medicine to treat IDA in this patient population. A potential approval will significantly boost sales of Auryxia.
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise
Our proven model does not conclusively show an earnings beat for Keryx this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP: Earnings ESP which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 18 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Keryx’s has a Zacks Rank #3, which increases the predictive power of ESP. However, 0.00% ESP makes surprise prediction difficult for the quarter.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +2.77% and a Zacks Rank #3. The company is scheduled to release results on May 2.
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #3. The company is expected to release results on May 8.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them? Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What to Expect from Keryx (KERX) Stock This Earnings Season?
Keryx Biopharmaceuticals, Inc. is expected to report first-quarter 2017 results on May 4. Last quarter, the company missed expectations by 18.52%. In fact, Keryx’s performance over the last four quarters has been disappointing. The company reported a wider-than-expected loss in three of the trailing four quarters, with an average negative surprise of 35.16%.
Keryx’s share price has increased 0.7% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 4.8%.
Let’s see how things are shaping up for the company this quarter.
Factors Influencing This Quarter
Apart from license fees, Keryx’s top line comprises revenues generated by its only marketed product Auryxia (ferric citrate). Auryxia is approved as tablets to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Notably, with Auryxia being the only approved product in Keryx’s portfolio, the company is entirely dependent on it for growth. Launched in the U.S. in late Dec 2014, Auryxia is still in its early stages of commercialization. Insufficient reimbursement and lengthy selling cycles have impacted the ramp up in Auryxia’s sales.
However, Keryx is working on its commercial efforts for Auryxia. In fact, the company is currently working on gaining formulary status for the drug. Additionally, it is operating on contracting the remaining insurance providers to expand patient access to Auryxia. This should enable more contact with the prescribers, both current physicians and those who have not prescribed Auryxia yet. The company expanded its field-based team to 95 sales representatives.
Moreover, Keryx is working on expanding ferric citrate's (the compound name for Auryxia in additional indications) label to include the treatment of iron-deficiency anemia (IDA) in patients with stage III–V non-dialysis dependent chronic kidney disease indication (NDD CKD). In Mar 2017, the FDA accepted the company’s supplemental New Drug Application (sNDA) for Auryxia for review (PDUFA date: Nov 6, 2017). If approved for this indication, Auryxia could be the first FDA-approved oral medicine to treat IDA in this patient population. A potential approval will significantly boost sales of Auryxia.
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise | Keryx Biopharmaceuticals, Inc. Quote
What Our Model Indicates
Our proven model does not conclusively show an earnings beat for Keryx this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP: Earnings ESP which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 18 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Keryx’s has a Zacks Rank #3, which increases the predictive power of ESP. However, 0.00% ESP makes surprise prediction difficult for the quarter.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Fibrogen Inc. (FGEN - Free Report) has an Earnings ESP of +23.81% and a Zacks Rank #3. The company is expected to release results on May 8. You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +2.77% and a Zacks Rank #3. The company is scheduled to release results on May 2.
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #3. The company is expected to release results on May 8.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>